{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:31:08Z","timestamp":1792593068661,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006586.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T00:00:00Z","timestamp":1329264000000}}],"reference-count":73,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006586.pub4","type":"journal-article","created":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T14:54:17Z","timestamp":1328885657000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Oral contraceptives containing drospirenone for premenstrual syndrome"],"prefix":"10.1002","author":[{"given":"Laureen M","family":"Lopez","sequence":"first","affiliation":[{"name":"FHI 360; Clinical Sciences; P.O. Box 13950 Research Triangle Park North Carolina USA 27709"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian A","family":"Kaptein","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center; Department of Medical Psychology; PO Box 9600 Leiden Netherlands 2300 RC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans M","family":"Helmerhorst","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center; Department of Gynaecology, Division of Reproductive Medicine and Dept. of Clinical Epidemiology; PO Box 9600 Albinusdreef 2 Leiden Netherlands NL 2300 RC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,15]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD006586.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/13625180008500387","article-title":"A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel","volume":"5","author":"Foidart","year":"2000","journal-title":"The European Journal of Contraception and Reproductive Health Care"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0003|cit2","first-page":"27-34; discussi","article-title":"Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder","volume":"7 Suppl 3","author":"Freeman","year":"2002","journal-title":"The European Journal of Contraception and Reproductive Health Care"},{"issue":"6","key":"10.1002\/14651858.CD006586.pub4-BIB0002|cit3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1089\/15246090152543148","article-title":"Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder","volume":"10","author":"Freeman","year":"2001","journal-title":"Journal of Women's Health and Gender-Based Medicine"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Kelly S Davies E Fearns S McKinnon C Carter R Gerlinger C Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study Clinical Drug Investigation 2010 325 36","DOI":"10.2165\/11535450-000000000-00000"},{"issue":"4","key":"10.1002\/14651858.CD006586.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00006250-200604001-00035","article-title":"Determining clinically meaningful benefit in the treatment of premenstrual dysphoric disorder (abstract)","volume":"107 Suppl","author":"Borenstein","year":"2006","journal-title":"Obstetrics & Gynecology"},{"issue":"6","key":"10.1002\/14651858.CD006586.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.contraception.2005.08.021","article-title":"Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation","volume":"72","author":"Pearlstein","year":"2005","journal-title":"Contraception"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Marr J Dennerstein L Ethinylestradiol 20 mcg\/drospirenone 3mg combined oral contraceptive administered in a 24\/4 regimen in the treatment of premenstrual dysphoric disorder-related symptoms and functional impairment: A randomized, multicenter, double-blind, parallel study (abstract) International Journal of Gynecology and Obstetrics 2009 619","DOI":"10.1016\/S0020-7292(09)62214-1"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Marr J Heinemann K Kunz M Rapkin A Ethinyl estradiol 20 \u03bcg\/drospirenone 3mg 24\/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder International Journal of Gynecology and Obstetrics 2011 103 7","DOI":"10.1016\/j.ijgo.2010.10.029"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Marr J Niknian M Shulman LP Lynen R Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24\/4 regimen Contraception 2011 81 6","DOI":"10.1016\/j.contraception.2010.10.010"},{"issue":"3","key":"10.1002\/14651858.CD006586.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/01.AOG.0000175834.77215.2e","article-title":"Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder","volume":"106","author":"Yonkers","year":"2005","journal-title":"Obstetrics & Gynecology"},{"issue":"4","key":"10.1002\/14651858.CD006586.pub4-BIB0011|cit11","first-page":"65","article-title":"Premenstrual Dysphoric Disorder symptom cluster improvement by cycle with an oral contraceptive (drospirenone 3 mg\/ethinyl estradiol 20 micrograms 24\/4) (abstract)","volume":"111 Suppl","author":"Yonkers","year":"2008","journal-title":"Obstetrics & Gynecology"},{"issue":"1","key":"10.1002\/14651858.CD006586.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/ejc.8.1.37.51","article-title":"Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms","volume":"8","author":"Apter","year":"2003","journal-title":"The European Journal of Contraception and Reproductive Health Care"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0013|cit13","first-page":"35-41; discussi","article-title":"Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being","volume":"7 Suppl 3","author":"Mansour","year":"2002","journal-title":"The European Journal of Contraception and Reproductive Health Care"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0014|cit14","unstructured":"Bayer A clinical study on Yasmin\u00ae vs. Marvelon\u00ae in Chinese women requiring contraception http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00185419"},{"issue":"6","key":"10.1002\/14651858.CD006586.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.contraception.2005.10.016","article-title":"Effect of a combination of ethinylestradiol 30 \u00b5g and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception","volume":"74","author":"Borges","year":"2006","journal-title":"Contraception"},{"issue":"5","key":"10.1002\/14651858.CD006586.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.ajog.2006.05.012","article-title":"Oral contraceptives and premenstrual symptoms: comparison of a 21\/7 and extended regimen","volume":"195","author":"Coffee","year":"2006","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Endrikat J Sandri M Gerlinger C Rubig A Schmidt W Fortier M A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight The European Journal of Contraception and Reproductive Health Care 2007 220 8","DOI":"10.1080\/13625180701440818"},{"issue":"1","key":"10.1002\/14651858.CD006586.pub4-BIB0018|cit18","first-page":"38","article-title":"Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial","volume":"44","author":"Fan","year":"2009","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Fan GS Bian ML Cheng LN Cao XM Huang ZR Han ZY Efficacy and safety of the combined oral contraceptive ethinylestradiol\/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial Clinical Drug Investigation 2010 387 96","DOI":"10.1007\/BF03256908"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0020|cit20","unstructured":"Joffe H Hall JE Soares CN Gottschall H Cohen LS Oral contraceptive pills to treat premenstrual worsening of depression 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, GA 2005"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Joffe H Petrillo LF Viguera AC Gottshcall H Soares CN Hall JE Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report Journal of Clinical Psychiatry 2007 1954 62","DOI":"10.4088\/JCP.v68n1218"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0023|cit22","doi-asserted-by":"crossref","unstructured":"Machado RB de Melo NR Maia H Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study Contraception 2010 215 22","DOI":"10.1016\/j.contraception.2009.10.010"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0022|cit23","doi-asserted-by":"crossref","unstructured":"Machado RB de Melo NR Maia H Cruz AM Effect of a continuous regimen of contraceptive combination of ethinylestradiol and drospirenone on lipid, carbohydrate and coagulation profiles Contraception 2010 102 6","DOI":"10.1016\/j.contraception.2009.08.009"},{"issue":"2","key":"10.1002\/14651858.CD006586.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0010-7824(00)00083-4","article-title":"An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen","volume":"61","author":"Parsey","year":"2000","journal-title":"Contraception"},{"issue":"1","key":"10.1002\/14651858.CD006586.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.contraception.2004.07.010","article-title":"A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 \u00b5g on premenstrual symptoms","volume":"71","author":"Sangthawan","year":"2005","journal-title":"Contraception"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0026|cit26","unstructured":"Schering AG Double-blind, randomized, multicenter, parallel group comparison of SH T 470 FA and Microgynon over 3 cycles in volunteers with premenstrual syndrome (PMS) Trial Protocol No. SH T 470 ZZ \/ 94160 (Dec 1992)"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0027|cit27","unstructured":"Bayer Schering Pharma AG YAZ Premenstrual Dysphoric Disorder (PMDD) in China http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00824187"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0028|cit28","unstructured":"Girdler S Rubinow DR Continuous oral contraceptive treatment in premenstrual dysphoric disorder (PMDD) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00927095"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0029|cit29","unstructured":"American College of Obstetricians and Gynecologists Premenstrual syndrome ACOG Practice Bulletin 2000 1 9"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists Noncontraceptive uses of hormonal contraceptives. ACOG Practice Bulletin No. 110 Obstetrics & Gynecology 2010 206 18","DOI":"10.1097\/AOG.0b013e3181cb50b5"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0032|cit32","unstructured":"American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) www.psychiatryonline.com\/dsmLibrary.aspx"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0022-3999(98)00042-7","article-title":"Cognitive therapy for premenstrual syndrome: a controlled trial","volume":"45","author":"Blake","year":"1998","journal-title":"Journal of Psychosomatic Research"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0034|cit34","first-page":"85","article-title":"Safety, efficacy, actions, and patient acceptability of drospirenone\/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder","volume":"1","author":"Breech","year":"2009","journal-title":"International Journal of Women's Health"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1192\/apt.7.6.469","article-title":"Premenstrual syndrome: an update on definitions, diagnosis and management","volume":"7","author":"Connolly","year":"2001","journal-title":"Advances in Psychiatric Treatment"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0036|cit36","unstructured":"CONSORT group CONSORT: Transparent reporting of trials http:\/\/www.consort-statement.org\/"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/9780470693926.ch15","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","volume-title":"Systematic Reviews in Health Care: Meta-analysis in Context","author":"Deeks","year":"2001"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/9780470693926.ch16","article-title":"Effect measures for meta-analysis of trials with binary outcomes","volume-title":"Systematic Reviews in Health Care: Meta-analysis in Context","author":"Deeks","year":"2001"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0039|cit39","first-page":"321","article-title":"Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00737-005-0103-y","article-title":"Daily Record of Severity of Problems (DRSP): reliability and validity","volume":"9","author":"Endicott","year":"2006","journal-title":"Archives of Women's Mental Health"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0041|cit41","unstructured":"US Food Drug Administration Drugs@FDA. FDA approved drug products http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.SearchResults_Browse&DrugInitial=Y"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/13697130500330309","article-title":"Added benefits of drospirenone for compliance","volume":"8 Suppl 3","author":"Foidart","year":"2005","journal-title":"Climacteric"},{"issue":"2","key":"10.1002\/14651858.CD006586.pub4-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003415.pub3","article-title":"Progesterone for premenstrual syndrome","author":"Ford","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"17","key":"10.1002\/14651858.CD006586.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1517\/14656566.2010.509344","article-title":"Therapeutic management of premenstrual syndrome","volume":"11","author":"Freeman","year":"2010","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"9","key":"10.1002\/14651858.CD006586.pub4-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003987","article-title":"Combination contraceptives: effects on weight","author":"Gallo","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/01674820009075612","article-title":"Prevalence of sexual abuse history in a sample of women seeking treatment for premenstrual syndrome","volume":"21","author":"Golding","year":"2000","journal-title":"Journal of Pyschosomatic Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0047|cit47","first-page":"223","article-title":"Assessing the assessment measures for menstrual cycle symptoms. A guide for researchers and clinicians","volume":"52","author":"Haywood","year":"2002","journal-title":"Journal of Pyschosomatic Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0048|cit48","first-page":"9","article-title":"Psychosocial associates of premenstrual symptoms and the moderating role of social support in a community sample","volume":"62","author":"Haywood","year":"2007","journal-title":"Journal of Pyschosomatic Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0140-6736(08)61191-5","article-title":"Premenstrual syndrome","volume":"372","author":"Helmerhorst","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0050|cit50","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 5.1[updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/01674820209074672","article-title":"A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder","volume":"23","author":"Hunter","year":"2002","journal-title":"Journal of Pyschosomatic Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.AOG.0000140686.66212.1e","article-title":"Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: A clinical primer for practitioners","volume":"104","author":"Johnson","year":"2004","journal-title":"Obstetrics & Gynecology"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0053|cit53","first-page":"359","article-title":"Treatment of premenstrual disorders","volume":"51","author":"Kroll","year":"2006","journal-title":"Journal of Reproductive Medicine"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00737-005-0102-z","article-title":"Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model","volume":"9","author":"Kurshan","year":"2006","journal-title":"Archives of Women's Mental Health"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/00006842-196811000-00006","article-title":"The Development of a Menstrual Distress Questionnaire","volume":"30","author":"Moos","year":"1968","journal-title":"Psychosomatic Medicine"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0058|cit58","unstructured":"Moos RH Menstrual Distress Questionnaire http:\/\/www.mindgarden.com\/products\/mdq.htm"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0059|cit59","first-page":"302","article-title":"Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: The Calendar of Premenstrual Experiences","volume":"76","author":"Mortola","year":"1990","journal-title":"Obstetrics & Gynecology"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1471-0528.1979.tb10582.x","article-title":"Treatment of premenstrual syndrome by spironolactone","volume":"86","author":"O'Brien","year":"1979","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mce.2003.10.030","article-title":"Drospirenone, a progestogen with antimineralocorticoid properties: a short review","volume":"217","author":"Oelkers","year":"2004","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.fertnstert.2003.08.030","article-title":"Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 \u00b5g of ethinyl estradiol","volume":"81","author":"Paoletti","year":"2004","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1-11; discussio","DOI":"10.1002\/sim.1328","article-title":"ICH E9 guideline 'Statistical principles for clinical trials': a case study","volume":"22","author":"Phillips","year":"2003","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0306-4530(03)00096-9","article-title":"A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder","volume":"28 Suppl 3","author":"Rapkin","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/01674820309039670","article-title":"Factor structure of the modified Moos Menstrual Distress Questionnaire: assessment of prospectively reported follicular, menstrual and premenstrual symptomatology","volume":"24","author":"Ross","year":"2003","journal-title":"Journal of Psychosomatic Obstetrics and Gynaecology"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM199801223380401","article-title":"Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome","volume":"338","author":"Schmidt","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(02)07750-4","article-title":"Allocation concealment in randomised trials: defending against deciphering","volume":"359","author":"Schulz","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(02)07882-0","article-title":"Sample size slippages in randomised trials: exclusions and the lost and wayward","volume":"359","author":"Schulz","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/humupd\/dmi046","article-title":"New progestagens for contraceptive use","volume":"12","author":"Sitruk-Ware","year":"2005","journal-title":"Human Reproduction Update"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0071|cit71","volume-title":"Evidence-based Medicine: How to Practice and Teach EBM","author":"Strauss","year":"2005"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3109\/00016349509021201","article-title":"Treatment of premenstrual syndrome by spironolactone: A double-blind, placebo-controlled study","volume":"74","author":"Wang","year":"1995","journal-title":"Acta Obstetricia et Gynecologica Scandinavica"},{"key":"10.1002\/14651858.CD006586.pub4-BIB0073|cit73","first-page":"339","article-title":"Premenstrual disorders. Prevalence, etiology and impact","volume":"51","author":"Winer","year":"2006","journal-title":"Journal of Reproductive Medicine"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006586.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006586.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:01:32Z","timestamp":1628532092000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006586.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecology and Fertility Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,2,15]]},"references-count":73,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006586.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,15]]}}}